» Articles » PMID: 14625217

Proton MR Spectroscopy of Mitochondrial Diseases: Analysis of Brain Metabolic Abnormalities and Their Possible Diagnostic Relevance

Overview
Specialty Neurology
Date 2003 Nov 20
PMID 14625217
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Purpose: Proton (hydrogen-1 [(1)H]) MR spectroscopy is a useful diagnostic tool in many metabolic diseases, but only scattered and inconclusive data are available on mitochondrial diseases. We performed MR imaging and (1)H MR spectroscopy of the brain in patients with different types of primary mitochondrial diseases to investigate the role of (1)H MR spectroscopy in the clinical evaluation of these disorders.

Methods: In 15 patients (11 adults, four children) with mitochondrial diseases, localized MR spectra were obtained at short TEs in cerebellar white matter, paratrigonal white matter, and parieto-occipital cortex that appeared normal on MR images. Additional spectra of basal ganglia and cortical gray matter structural lesions were obtained in three patients.

Results: A significant choline reduction and N-acetylaspartate reduction were found in areas that appeared normal on MR images. Lactate was never found in areas that appeared normal on MR images, except in two children in whom MR studies were performed during episodes of symptom exacerbation and revealed elevated lactate both in areas that appeared damaged on MR images and in normal-appearing areas. An additional abnormal signal at 0.9 ppm was found in a consistent number of studies.

Conclusion: (1)H MR spectroscopy proved to be a useful investigational tool for mitochondrial diseases, as it enabled detection of metabolic abnormalities even in areas of brain that appeared normal on MR images, especially when it was performed during episodes of clinical relapses or clinical exacerbation.

Citing Articles

Mitochondrial Dysfunction in Cardiac Disease: The Fort Fell.

Paraskevaidis I, Kourek C, Farmakis D, Tsougos E Biomolecules. 2025; 14(12.

PMID: 39766241 PMC: 11673776. DOI: 10.3390/biom14121534.


Imaging brain glucose metabolism in vivo reveals propionate as a major anaplerotic substrate in pyruvate dehydrogenase deficiency.

Marin-Valencia I, Kocabas A, Rodriguez-Navas C, Miloushev V, Gonzalez-Rodriguez M, Lees H Cell Metab. 2024; 36(6):1394-1410.e12.

PMID: 38838644 PMC: 11187753. DOI: 10.1016/j.cmet.2024.05.002.


Advancing the neuroimaging diagnosis and understanding of mitochondrial disorders.

Alves C, Whitehead M Neurotherapeutics. 2024; 21(1):e00324.

PMID: 38306952 PMC: 10903090. DOI: 10.1016/j.neurot.2024.e00324.


Magnetic resonance spectroscopy in MELAS syndrome: correlation with CSF and plasma metabolite levels and change after glutamine supplementation.

Guerrero-Molina M, Bernabeu-Sanz A, Ramos-Gonzalez A, Morales-Conejo M, Delmiro A, Dominguez-Gonzalez C Neuroradiology. 2023; 66(3):389-398.

PMID: 38114794 DOI: 10.1007/s00234-023-03263-1.


A child with mitochondrial DNA deletion presenting diabetes mellitus as an initial symptom.

Nemoto K, Sano K, Sato S, Maeda Y, Murayama K, Takanashi J Radiol Case Rep. 2022; 17(9):2915-2918.

PMID: 35755118 PMC: 9218280. DOI: 10.1016/j.radcr.2022.05.061.


References
1.
Felber S, Sperl W, Chemelli A, Murr C, Wendel U . Maple syrup urine disease: metabolic decompensation monitored by proton magnetic resonance imaging and spectroscopy. Ann Neurol. 1993; 33(4):396-401. DOI: 10.1002/ana.410330412. View

2.
Bitsch A, Bruhn H, Vougioukas V, Stringaris A, Lassmann H, Frahm J . Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy. AJNR Am J Neuroradiol. 1999; 20(9):1619-27. PMC: 7056180. View

3.
Bruhn H, Kruse B, Korenke G, Hanefeld F, Hanicke W, Merboldt K . Proton NMR spectroscopy of cerebral metabolic alterations in infantile peroxisomal disorders. J Comput Assist Tomogr. 1992; 16(3):335-44. DOI: 10.1097/00004728-199205000-00001. View

4.
Wang Z, Zimmerman R . Proton MR spectroscopy of pediatric brain metabolic disorders. Neuroimaging Clin N Am. 1998; 8(4):781-807. View

5.
Stockler S, Hanefeld F, Frahm J . Creatine replacement therapy in guanidinoacetate methyltransferase deficiency, a novel inborn error of metabolism. Lancet. 1996; 348(9030):789-90. DOI: 10.1016/s0140-6736(96)04116-5. View